Table 2.
Treatment response
| Total | 1st TKI | 1st RT | ||
|---|---|---|---|---|
| Response | N = 104 | N = 65 | N = 39 | P‐value |
| Best overall response | ||||
| CR | 1 | 0 | 1 | — |
| PR | 63 | 39 | 24 | — |
| SD (include non‐CR/non‐PD) | 22 | 13 | 9 | — |
| PD | 10 | 8 | 2 | — |
| Not evaluated | 8 | 5 | 3 | — |
| Response rate | 64 (62%) | 39 (60%) | 25 (64%) | 0.8353 |
| Disease control rate | 86 (83%) | 52 (80%) | 34 (87%) | 0.4289 |
| Best CNS response | ||||
| CR | 15 | 10 | 5 | — |
| PR | 23 | 14 | 9 | — |
| SD (include non‐CR/non‐PD) | 46 | 27 | 19 | — |
| PD | 7 | 6 | 1 | — |
| Not evaluated | 13 | 8 | 5 | — |
| Response rate | 38 (37%) | 24 (37%) | 14 (36%) | 1.0000 |
| Disease control rate | 84 (81%) | 51 (78%) | 33 (85%) | 0.6082 |
CR, complete response; PD, progression of disease; PR, partial response; RT, radiotherapy; SD, stable disease; TKI, tyrosine kinase inhibitor; WBRT, whole brain radiotherapy.